Cambridge, Massachusetts, USA
At Zumutor, we are on a mission to develop novel novel immuno onco-therapeutics that drive transformational improvements in cancer treatment through NK cell engagement. We leverage our proven proprietary antibody discovery- INABLR™ for fast track Antibody discovery and development. Our team works in collaboration with a world class Scientific Advisory Board with expertise in immuno-oncology and clinical development. Our lead asset (ZM008) is a first-in-class antibody that targets certain receptors that blocks NK cell inhibitory signal and enables NK cell activation to generate a potent immune response. Development is on track for an IND filing by Q2 2022 and Phase 1 clinical trial thereafter. We are headquartered in CIC Cambridge Campus, MA and R&D is carried out at ISO certified lab in Bangalore, India
No key contacts have been added to this profile yet.
No reviews have been added to this profile yet.
This is the company profile page for Zumutor Biologics on the Pharmaceutical Services Directory. Companies listed on the directory can update their business information free of charge. If this is your company and you'd like to claim this profile, please Contact Us.
